Premium
Inhibitors of Apoptotic Proteins: New Targets for Anticancer Therapy
Author(s) -
Saleem Mohammad,
Qadir Muhammad Imran,
Perveen Nadia,
Ahmad Bashir,
Saleem Uzma,
Irshad Tehseen,
Ahmad Bashir
Publication year - 2013
Publication title -
chemical biology and drug design
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 77
eISSN - 1747-0285
pISSN - 1747-0277
DOI - 10.1111/cbdd.12176
Subject(s) - xiap , survivin , inhibitor of apoptosis , apoptosis , caspase , cancer research , microbiology and biotechnology , biology , chemistry , programmed cell death , biochemistry
Inhibitors of apoptotic proteins ( IAP s) can play an important role in inhibiting apoptosis by exerting their negative action on caspases (apoptotic proteins). There are eight proteins in this family: NAIP / BIRC 1/ NLRB , cellular IAP 1 ( cIAP 1)/human IAP 2/ BIRC 2, cellular IAP 2 ( cIAP 2)/human IAP 1/ BIRC 3, X ‐linked IAP ( XIAP )/ BIRC 4, survivin/ BIRC 5, baculoviral IAP repeat ( BIR )‐containing ubiquitin‐conjugating enzyme/apollon/ BIRC 6, livin/melanoma‐ IAP ( ML ‐ IAP )/ BIRC 7/ KIAP , and testis‐specific IAP ( T s‐ IAP )/ hILP ‐2/ BIRC 8. Deregulation of these inhibitors of apoptotic proteins ( IAP s) may push cell toward cancer and neurodegenerative disorders. Inhibitors of apoptotic proteins ( IAP s) may provide new target for anticancer therapy. Drugs may be developed that are inhibiting these IAP s to induce apoptosis in cancerous cells.